Skip to content

Study · Observational study · n = 169 · 2025

3 results

Unveiling lymphocyte dynamics: Navigating postoperative immune landscapes in gastric cancer patients undergoing laparoscopic D2 gastrectomy.

Gao C, Zhu L, Tong YX, Zhang S

International journal of immunopathology and pharmacology1 Jan 2025Cited by 2 (Europe PMC)

PMID40650581 (opens in a new tab)PMCIDPMC12255863 (opens in a new tab)DOI10.1177/03946320251352344 (opens in a new tab)PepBankPUB-40650581
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In gastric cancer patients after laparoscopic D2 gastrectomy, Tα1 treatment significantly reduced the decline in T cell counts.

    In plain wordsIn gastric cancer patients after surgery, thymosin alpha‑1 was linked to a smaller fall in T cell counts.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePostoperative decline in T cell count
    Study

    n = 169

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin alpha 1 (Tα1) treatment proved to be a protective factor, significantly reducing the decline in T and B cell counts (p = 0.05).
    1 context sentence
    Summary · context
    We retrospectively analyzed clinicopathological data from 169 gastric cancer patients, focusing on perioperative lymphocyte subset variations.
  2. 02HumanObservational studyEfficacy outcome

    In gastric cancer patients after laparoscopic D2 gastrectomy, Tα1 treatment significantly reduced the decline in B cell counts.

    In plain wordsIn gastric cancer patients after surgery, thymosin alpha‑1 was linked to a smaller fall in B cell counts.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePostoperative decline in B cell count
    Study

    n = 169

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin alpha 1 (Tα1) treatment proved to be a protective factor, significantly reducing the decline in T and B cell counts (p = 0.05).
    1 context sentence
    Summary · context
    We retrospectively analyzed clinicopathological data from 169 gastric cancer patients, focusing on perioperative lymphocyte subset variations.
  3. 03HumanObservational studyEfficacy outcome

    In multivariate analysis, Tα1 therapy was an independent predictor of lower risk of T cell reduction (HR 0.15) in gastric cancer patients after surgery.

    In plain wordsIn gastric cancer patients after surgery, thymosin alpha‑1 was linked to a lower risk of T cell loss.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIndependent predictor of T cell reduction
    Study

    n = 169

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    HR for T cell reduction
    0.15
    Tα1 therapy

    Source sentences

    Summary
    Multivariate analysis identified higher Interleukin-1β levels (HR = 3.66, p = 0.01), longer operation times (HR = 2.98, p = 0.02), and Tα1 therapy (HR = 0.15, p = 0.01) as independent predictors of T cell reduction.
    1 context sentence
    Summary · context
    We retrospectively analyzed clinicopathological data from 169 gastric cancer patients, focusing on perioperative lymphocyte subset variations.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.